Study of Clonal Hematopoiesis and Therapy-Related Blood Cancers in Patients With Ovarian or Other Solid Tumors

What this Trial Is About

Researchers are investigating clonal hematopoiesis and therapy-emergent myeloid neoplasms in patients who have ovarian or other solid cancers. The study aims to identify risk factors and possible genetic or environmental causes for developing these blood cancers. This observational study involves patients with a history of certain solid tumors or blood disorders related to cancer treatment. Participants in this study provide blood samples and complete surveys to help researchers understand the relationship between genetic markers and the development of blood cancers after cancer therapy. Medical records are also reviewed to gather comprehensive information. There are no treatments given as part of this study, and it focuses on observation and data collection. During the study, researchers will measure the presence and changes of specific genetic mutations in blood cells, especially the TP53 mutation, over up to five years. They will assess how these changes relate to the risk of developing therapy-related blood cancers. Participants medical histories, blood tests, and survey responses will be monitored regularly to track these outcomes and better understand the progression from non-cancerous mutations to blood cancers.

Clonal Hematopoiesis and Therapy-Emergent Myeloid Neoplasms in Patients With Cancers, CHANCES Study